Treatment Interruption of Natalizumab
Completed · Phase 2 · Has a placebo group
Conditions studied: Relapsing Remitting Multiple Sclerosis
In brief
This is a randomized, rater blinded trial in patients who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab. The main purpose of this study is to find out the following, when participants stop taking natalizumab for 24 weeks: * when MS symptoms return, and * if other drugs for MS may help control MS symptoms during the natalizumab-interruption period. This study will also explore how quickly the effects of natalizumab return after resuming natalizumab dosing.
Key facts
- Study ID
- NCT01071083
- Run by
- Biogen
- People needed
- 175
- Starts
- 2010-03-01
- Expected to finish
- 2011-11-01
- Last updated by the study team
- 2013-09-19
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Cullman, Alabama, United States
- Research Site — San Francisco, California, United States
- Research Site — Fort Collins, Colorado, United States
- Research Site — Pompano Beach, Florida, United States
- Research Site — Atlanta, Georgia, United States
- Research Site — Atlanta, Georgia, United States
- Research Site — Chicago, Illinois, United States
- Research Site — Lake Barrington, Illinois, United States
- Research Site — Des Moines, Iowa, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Buffalo, New York, United States
- Research Site — Latham, New York, United States
- Research Site — Patchogue, New York, United States
- Research Site — Charlotte, North Carolina, United States
- Research Site — Raleigh, North Carolina, United States
- Research Site — Cleveland, Ohio, United States
- Research Site — Uniontown, Ohio, United States
- Research Site — Salt Lake City, Utah, United States
- Research Site — Seattle, Washington, United States
- Research Site — Freiburg im Breisgau, Baden-Wurttemberg, Germany
- Research Site — München, Bavaria, Germany
- Research Site — Hennigsdorf, Brandenburg, Germany
- Research Site — Hamburg, Free and Hanseatic City of Hamburg, Germany
- Research Site — Marburg, Hesse, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.